Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation

Breast cancer is the most common neoplasm diagnosed in women around the world. Checkpoint inhibitors, targeting the programmed death receptor-1 or ligand-1 (PD-1/PD-L1) axis, have dramatically changed the outcome of cancer treatment. These therapies have been recently considered as alternatives for...

Descripción completa

Detalles Bibliográficos
Autores principales: Segovia-Mendoza, Mariana, Romero-Garcia, Susana, Lemini, Cristina, Prado-Garcia, Heriberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808819/
https://www.ncbi.nlm.nih.gov/pubmed/33506060
http://dx.doi.org/10.1155/2021/6668573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808819/
https://www.ncbi.nlm.nih.gov/pubmed/33506060
http://dx.doi.org/10.1155/2021/6668573

Ejemplares similares